Cocrystal Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-17.5	-17.98	-38.84	-14.19	-9.65	Upgrade
Depreciation & Amortization	0.13	0.19	0.19	0.38	0.34	Upgrade
Asset Writedown & Restructuring Costs	-	-	19.09	-	-	Upgrade
Stock-Based Compensation	0.64	0.8	0.86	0.72	0.66	Upgrade
Other Operating Activities	0.11	-0.01	-0.02	-0.24	-0.12	Upgrade
Change in Accounts Receivable	-	-	-	0.56	0.09	Upgrade
Change in Accounts Payable	-0.9	2.05	-0.32	0.22	-0.92	Upgrade
Change in Other Net Operating Assets	1.36	0.47	-1.68	-0.17	-0.23	Upgrade
Operating Cash Flow	-16.49	-14.67	-21.44	-12.72	-9.83	Upgrade
Capital Expenditures	-0.01	-0.12	-0.07	-0.05	-0.24	Upgrade
Investing Cash Flow	-0.01	-0.12	-0.07	-0.05	-0.24	Upgrade
Long-Term Debt Repaid	-	-0.01	-0.03	-0.04	-0.12	Upgrade
Net Debt Issued (Repaid)	-	-0.01	-0.03	-0.04	-0.12	Upgrade
Issuance of Common Stock	-	4	-	38.51	35.78	Upgrade
Financing Cash Flow	-	3.99	-0.03	38.47	35.66	Upgrade
Net Cash Flow	-16.49	-10.79	-21.54	25.7	25.59	Upgrade
Free Cash Flow	-16.49	-14.78	-21.51	-12.77	-10.07	Upgrade
Free Cash Flow Margin	-	-	-	-	-500.00%	Upgrade
Free Cash Flow Per Share	-1.62	-1.53	-2.64	-1.73	-2.19	Upgrade
Levered Free Cash Flow	-10.29	-10.01	-13.12	-7.28	-6.25	Upgrade
Unlevered Free Cash Flow	-10.29	-10.01	-13.12	-7.28	-6.24	Upgrade
Change in Net Working Capital	-0.12	-2.34	2.75	-0.56	1.01	Upgrade

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q